[x_section parallax=”true” bg_image=”https://reconstructivesurgerytrials.net/wp-content/uploads/2015/11/Metastatic_Melanoma_Cells_Nci-vol-9872-300.jpg” bg_color=”” style=”margin: 0px 0px 0px 0px; padding: 45px 0px 45px 0px; “][x_row inner_container=”true” marginless_columns=”false” bg_color=”” style=”margin: 0px auto 0px auto; padding: 0px 0px 0px 0px; “][x_column bg_color=”” type=”1/1″ style=”padding: 0px 0px 0px 0px; “][x_gap size=”150px”][/x_column][/x_row][/x_section][x_section style=”margin: 0px 0px 0px 0px; padding: 0px 0px 0px 0px; “][x_row inner_container=”true” marginless_columns=”false” bg_color=”” style=”margin: 0px auto 0px auto; padding: 0px 0px 0px 0px; “][x_column bg_color=”#ffffff” type=”2/3″ class=”left-text ” style=”padding: 0px 0px 0px 0px; “][x_gap size=”20px”][x_custom_headline level=”h2″ looks_like=”h3″ accent=”false”]MelMarT[/x_custom_headline][x_text]Melanoma Margins Trial[/x_text][x_alert type=”success” close=”false” heading=”MelMarT pilot results published”]The MelMarT pilot results have been published in the Annals of Surgical Oncology. They demonstrate a definitive trial is feasible.[/x_alert][x_text]Update 27/08/2016: MelMarT has closed to patient recruitment and has now entered the surveillence phase.
A Phase III, multi-centre, multi-national randomised control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma on disease recurrence and survival.
This study will determine whether there is a difference in local recurrence rates and melanoma survival rates for patients treated with either a 1cm excision margin or 2cm margin for both intermediate & high risk melanomas.
Who is it for?
You may be eligible to joint this study if you aged 18 years or above and have been diagnosed with a primary invasive cutaneous melanoma greater than 1mm thick.
Study details
Whilst patients with a primary invasive melanoma are generally recommended to undergo excision of the primary lesion with a wide margin, there is evidence that less radical margins of excision may be just as safe. Participants in this study are randomly allocated (by chance) to one of two groups. Participants in one group will undergo surgery with the 2cm excision margin, whilst participants in the other group will undergo surgery with a 1cm excision margin.
Participants will be monitored for up to 60 months, in order to determine melanoma recurrence, survival rates and quality of life, and additionally, adverse events and health resource usage.
Intervention
This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with a primary invasive cutaneous melanomas >=1mm thick to determine differences in the rate of local recurrence and melanoma specific survival.
ARM A: Experimental Arm
Wide Local Excision = 1cm Margin
+ Sentinel Lymph Node Biopsy
+/- Reconstruction
These procedures need to be performed +
Comparator
ARM B:Control Arm
Wide Local Excision = 2cm Margin
+ Sentinel Lymph Node Biopsy
+/- Reconstruction
These procedures need to be performed +[/x_text][/x_column][x_column bg_color=”” type=”1/3″ style=”padding: 0px 0px 0px 0px; “][x_gap size=”20px”][x_accordion][x_accordion_item title=”Status” open=”true”][icon_list] [icon_list_item type=”check-square-o”]Protocol development [/icon_list_item] [icon_list_item type=”check-square-o”]NRES approval [/icon_list_item][icon_list_item type=”check-square-o”]Data collection [/icon_list_item] [icon_list_item type=”check-square-o”]Data analysis[/icon_list_item] [icon_list_item type=”check-square-o”]Manuscript submission [/icon_list_item][icon_list_item type=”check-square-o”]Publication [/icon_list_item][/icon_list] [/x_accordion_item][x_accordion_item title=”UK Steering group” open=”false”]Marc Moncrieff
Principal Investigator
Consultant Plastic Surgeon
Norfolk and Norwich University Hospitals NHS Foundation Trust[/x_accordion_item][x_accordion_item title=”Collaborators” open=”false”]Australia and New Zealand Melanoma Trials Group
The University of Sydney
The Poche Centre
40 Rocklands Road
North Sydney NSW 2060 Australia
Telephone: +61 2 9911 7200
Fax: +61 2 9954 9435
anzmtg@melanoma.org.au[/x_accordion_item][x_accordion_item title=”Trials Unit” open=”false”]Lead unit: Norfolk and Norwich University Hospitals NHS Foundation Trust[/x_accordion_item][x_accordion_item title=”Funding” open=”false”]NIHR Portfolio[/x_accordion_item][x_accordion_item title=”Downloads” open=”false”]Moncrieff MD, Gyorki D, Saw R, Spillane AJ, Peach H, Oudit D, Geh J, Dziewulski P, Wilson E, Matteucci P, Pritchard-Jones R, Olofsson Bagge R, Wright FC, Crampton N, Cassell O, Jallali N, Berger A, Kelly J, Hamilton S, Durrani A, Lo S, Paton E, Henderson MA. 1 Versus 2-cm Excision Margins for pT2-pT4 Primary Cutaneous Melanoma (MelMarT): A Feasibility Study. Ann Surg Oncol. 2018 Sep;25(9):2541-2549. doi: 10.1245/s10434-018-6470-1. Epub 2018 May 30. Erratum in: Ann Surg Oncol. 2018 Jun 26; PMID: 29850955
ANZ Melanoma Trials Group[/x_accordion_item][x_accordion_item title=”Contact” open=”true”]Marc Moncrieff via his website.[/x_accordion_item][/x_accordion][/x_column][/x_row][/x_section]